Apellis Pharmaceuticals Inc (APLS) Stock Price, Quote & News

Company Profile

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops EMPAVELI to treat C3 glomerulopathy and immune complex membranoproli...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 977 5700

Website: apellis.com

Address:

100 Fifth Avenue, Waltham, United States

The_Fudge_ster Mar. 20 at 7:47 PM

$APLS continues to be a steaming pile of shit, but potentially a steaming pile of shit I am willing to tango with next week if we fall into 15-16 range.

0 · Reply

Rabinovich Mar. 19 at 8:07 AM

$APLS The sad truth is that the type of market Syfovre occupies cannot be succesfuly served by a SMID. It requires large sales dept, synergies, and most importantly huge marketing budget. The management know this but continue to waste the potential, as they are in a comfortable position in which they cannot lose. The losers are the investors and the patients. The big surpise for me is that there seems to be no interest by BP. Probably because management is asking for way too much. At this point of time i do not believe anymore that the management can execute and only hope that at some point of time management will accept some reasonable offer, e.g. around $30 or so.

1 · Reply

BB_88_ Mar. 18 at 9:28 PM

$APLS almost got in today. Will give it a few more days

0 · Reply

scott52 Mar. 18 at 9:04 PM

$APLS Except I'd like to just jam it into his fucking eyeball.

0 · Reply

Spanner1968 Mar. 18 at 7:03 PM

$APLS Yuck!!

1 · Reply

Whiskeyunderthebed Mar. 18 at 6:19 PM

$APLS

0 · Reply

Rabinovich Mar. 18 at 5:04 PM

$APLS management completely ruined the potential of the assets and the prospects of this company.

0 · Reply

The_Fudge_ster Mar. 18 at 2:49 PM

$APLS my god this is a steaming pile of shit. Also, not a bad buy in the mid teens despite that. I may go long again.

0 · Reply

Whiskeyunderthebed Mar. 16 at 4:06 PM

$APLS complete garbage...clean the house.

1 · Reply

Georgeson Mar. 12 at 6:36 PM

$APLS Where is the freaking bottom? Cedric and other insiders if they know anything about running a public company should buy some shares on the open market. So glad I sold all my shares at $26 plus and bought sndx. But I am tempted to buy back in.

0 · Reply

Apellis Pharmaceuticals, Inc. (APLS) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Mar 2, 2026, 7:00 AM EST - 19 days ago

Apellis Announces Mikael Dolsten, M.D., Ph.D., to Join Board of Directors

Feb 24, 2026, 11:48 AM EST - 25 days ago

Apellis Pharmaceuticals, Inc. (APLS) Q4 2025 Earnings Call Transcript

Feb 24, 2026, 7:05 AM EST - 25 days ago

Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

Feb 23, 2026, 7:00 AM EST - 26 days ago

Apellis Pharmaceuticals to Present at the TD Cowen 46th Annual Health Care Conference

Feb 19, 2026, 7:00 AM EST - 4 weeks ago

Apellis Announces Eight Oral Presentations at the 49th Macula Society Annual Meeting

Feb 10, 2026, 7:00 AM EST - 5 weeks ago

Apellis Pharmaceuticals to Host Conference Call on February 24, 2026, to Discuss Fourth Quarter and Full Year 2025 Financial Results

Jan 27, 2026, 6:02 PM EST - 7 weeks ago

TTM Technologies, Dutch Bros, Advanced Energy Industries, and American Healthcare REIT Set to Join S&P MidCap 400; Others to Join S&P SmallCap 600

AEIS AHR AMRX BROS CADE CIVI CMA

Jan 21, 2026, 1:14 PM EST - 2 months ago

Apellis Valuation Ignores Empaveli Potential, Says Analyst

Jan 12, 2026, 6:16 PM EST - 2 months ago

Apellis Pharmaceuticals, Inc. (APLS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 7:00 AM EST - 2 months ago

Apellis Highlights Commercial Execution and Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference

Jan 5, 2026, 7:00 AM EST - 2 months ago

Apellis Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 3, 2025, 5:05 PM EST - 3 months ago

The New England Journal of Medicine Publishes Positive Phase 3 VALIANT Results of EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN

Dec 3, 2025, 4:43 PM EST - 3 months ago

Apellis Pharmaceuticals, Inc. (APLS) Presents at Evercore 8th Annual Healthcare Conference Transcript

Dec 2, 2025, 6:53 PM EST - 3 months ago

Apellis Pharmaceuticals, Inc. (APLS) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Nov 25, 2025, 7:00 AM EST - 4 months ago

Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences

Nov 12, 2025, 4:41 PM EST - 4 months ago

Apellis Pharmaceuticals, Inc. (APLS) Presents at Stifel 2025 Healthcare Conference Transcript

Nov 12, 2025, 7:00 AM EST - 4 months ago

Apellis Announces 5-Year GALE Data Showing SYFOVRE® (pegcetacoplan injection) Delayed Progression of Geographic Atrophy by ~1.5 Years

Nov 5, 2025, 7:00 AM EST - 4 months ago

Apellis Pharmaceuticals to Present at the Stifel 2025 Healthcare Conference

Oct 30, 2025, 8:16 PM EDT - 5 months ago

Apellis Pharmaceuticals, Inc. (APLS) Q3 2025 Earnings Call Transcript

Oct 30, 2025, 7:05 AM EDT - 5 months ago

Apellis Pharmaceuticals Reports Third Quarter 2025 Financial Results

Oct 20, 2025, 7:00 AM EDT - 5 months ago

New One-Year Data Reinforcing the Robust and Sustained Efficacy of EMPAVELI® (pegcetacoplan) in C3G and Primary IC-MPGN to be Presented at ASN Kidney Week

Oct 16, 2025, 7:00 AM EDT - 5 months ago

Apellis Pharmaceuticals to Host Conference Call on October 30, 2025, to Discuss Third Quarter 2025 Financial Results

Sep 30, 2025, 4:34 PM EDT - 6 months ago

Apellis Pharmaceuticals: Maintaining "Buy" Rating With Continued EMPAVELI Expansions Beyond PNH And C3G-Disorders

Sep 9, 2025, 12:55 PM EDT - 6 months ago

Apellis Pharmaceuticals, Inc. (APLS) Presents At Baird Global Healthcare Conference (Transcript)

Sep 4, 2025, 11:20 AM EDT - 7 months ago

Apellis Pharmaceuticals, Inc. (APLS) Presents At Cantor Global Healthcare Conference 2025 (Transcript)

Sep 3, 2025, 11:24 AM EDT - 7 months ago

Apellis Pharmaceuticals, Inc. (APLS) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Aug 14, 2025, 12:12 PM EDT - 7 months ago

Apellis Pharmaceuticals: Restart Of Growth Story After Empaveli's New Approval

Aug 2, 2025, 4:23 AM EDT - 8 months ago

Apellis Pharmaceuticals, Inc. (APLS) Q2 2025 Earnings Call Transcript

Aug 1, 2025, 2:29 PM EDT - 8 months ago

Apellis Pharmaceuticals: The Picture Becomes Clearer

Jul 31, 2025, 7:05 AM EDT - 8 months ago

Apellis Pharmaceuticals Reports Second Quarter 2025 Financial Results

Jul 29, 2025, 12:12 PM EDT - 8 months ago

FDA Approval For Empaveli Marks Key Milestone In Apellis' Rare Disease Portfolio

Jul 28, 2025, 7:19 PM EDT - 8 months ago

FDA Approves Apellis' EMPAVELI® (pegcetacoplan) as the First C3G and Primary IC-MPGN Treatment for Patients 12 and Older

Jul 24, 2025, 7:00 AM EDT - 8 months ago

Apellis Pharmaceuticals to Host Conference Call on July 31, 2025, to Discuss Second Quarter 2025 Financial Results

Jul 15, 2025, 7:00 AM EDT - 8 months ago

Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting

Jul 1, 2025, 7:35 AM EDT - 9 months ago

Sobi to amend existing agreement with Apellis for ex-U.S. royalties of Aspaveli® (systemic pegcetacoplan)

Jul 1, 2025, 7:00 AM EDT - 9 months ago

Apellis to Receive up to $300 Million from Royalty Purchase Agreement with Sobi for Ex-U.S. Royalties of Aspaveli® (systemic pegcetacoplan)

Jun 6, 2025, 9:15 AM EDT - 10 months ago

Apellis and Sobi Announce EMPAVELI® (pegcetacoplan) Showed Sustained Efficacy at One Year in Phase 3 Study for C3G and Primary IC-MPGN

Jun 4, 2025, 7:00 AM EDT - 10 months ago

Apellis Pharmaceuticals to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

May 20, 2025, 9:28 AM EDT - 10 months ago

Apellis Pharmaceuticals: Have Some Patience

May 7, 2025, 1:18 PM EDT - 11 months ago

Apellis Pharmaceuticals, Inc. (APLS) Q1 2025 Earnings Call Transcript

May 7, 2025, 7:00 AM EDT - 11 months ago

Apellis Pharmaceuticals Reports First Quarter 2025 Financial Results

May 6, 2025, 7:00 AM EDT - 11 months ago

Apellis Pharmaceuticals to Present at Upcoming Investor Conferences

Apr 30, 2025, 7:00 AM EDT - 11 months ago

Apellis Pharmaceuticals to Host Conference Call on May 7, 2025, to Discuss First Quarter 2025 Financial Results

Apr 21, 2025, 7:00 AM EDT - 11 months ago

Apellis Announces Craig Wheeler to Join the Board of Directors

Apr 1, 2025, 2:11 PM EDT - 1 year ago

FDA Reviews Kidney Disease Drug From Apellis Pharmaceuticals

Apr 1, 2025, 7:00 AM EDT - 1 year ago

Apellis Announces FDA Acceptance and Priority Review of the Supplemental New Drug Application for EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN

Mar 5, 2025, 2:06 PM EST - 1 year ago

Apellis Pharmaceuticals: A Mixed Bag

Mar 5, 2025, 2:04 PM EST - 1 year ago

Apellis Lead Drug Pegcetacoplan Represents Differentiated Asset: JP Morgan Analyst

Mar 2, 2025, 2:08 AM EST - 1 year ago

Apellis Pharmaceuticals, Inc. (APLS) Q4 2024 Earnings Call Transcript

The_Fudge_ster Mar. 20 at 7:47 PM

$APLS continues to be a steaming pile of shit, but potentially a steaming pile of shit I am willing to tango with next week if we fall into 15-16 range.

0 · Reply

Rabinovich Mar. 19 at 8:07 AM

1 · Reply

BB_88_ Mar. 18 at 9:28 PM

$APLS almost got in today. Will give it a few more days

0 · Reply

scott52 Mar. 18 at 9:04 PM

$APLS Except I'd like to just jam it into his fucking eyeball.

0 · Reply

Spanner1968 Mar. 18 at 7:03 PM

$APLS Yuck!!

1 · Reply

Whiskeyunderthebed Mar. 18 at 6:19 PM

$APLS

0 · Reply

Rabinovich Mar. 18 at 5:04 PM

$APLS management completely ruined the potential of the assets and the prospects of this company.

0 · Reply

The_Fudge_ster Mar. 18 at 2:49 PM

$APLS my god this is a steaming pile of shit. Also, not a bad buy in the mid teens despite that. I may go long again.

0 · Reply

Whiskeyunderthebed Mar. 16 at 4:06 PM

$APLS complete garbage...clean the house.

1 · Reply

Georgeson Mar. 12 at 6:36 PM

0 · Reply

Spanner1968 Mar. 11 at 7:14 PM

$APLS POS, trying to shake everyone out.....

1 · Reply

scott52 Mar. 11 at 4:33 PM

$APLS Bought back at $19.15. For a trade. Saved 15% dumping at $22.50. I can't make any money holding this stock (in fact, I lost money). Figured I may as well try trading it to claw something back. Man, I don't trust this stock AT ALL. I won't be suprised if it plummets to $16 now that I own it again.

0 · Reply

RunnerSignals Mar. 10 at 8:38 PM

Top stock upgrades today in the BUZZ $APLS $ASML $CAVA $IQV $PLUG steady gains post-rating changes, correlation to sector news, late buyers pushed close higher https://stocksrunner.com/news/2026-03-10-top-stock-upgrades-today-in-the-buzz

0 · Reply

Longboardsoul Mar. 10 at 6:27 PM

$APLS I think we can all agree that the real winner here is Cedric's ex wife. Homegirl realized he was a loser and split. Hope she took him for a few mil. Guy is a baby back Belgian bitch

0 · Reply

Whiskeyunderthebed Mar. 10 at 3:00 PM

$APLS

0 · Reply

The_Fudge_ster Mar. 10 at 2:15 PM

$APLS amazing watching $DNTH rip while APLS just sits and wallows in the misery of the teens. Amazing how a company that claims to be the leader in complement has whiffed so badly while others succeed.

1 · Reply

philosophernutz Mar. 8 at 1:34 AM

$APLS Get ready boys. Dolstens was hired to help sell APLS. His stock options fully accelerate if there's a change in control of the company. Form 3 Mar 3, 2026 Initial Statement of Beneficial Ownership. Confirms Dolsten currently owns 0 shares outright. He is purely an "Equity-Incentivized" director. Form 4 Mar 3, 2026 Grant of 24,135 Options and 14,312 RSUs. The exercise price for his options is $20.96. This is his "breakeven" point. The Trigger Full Acceleration SEC Exhibit 10.1 The contract explicitly states all 38,447 units vest immediately upon a "Change in Control.

3 · Reply

Whiskeyunderthebed Mar. 7 at 4:45 PM

$APLS This is what we need: Servier to build cancer drug pipeline with $2.5B purchase of Day One

0 · Reply

erevnon Mar. 5 at 2:58 PM

Mizuho maintains Apellis Pharmaceuticals $APLS at Neutral and raises the price target from $19 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

Spanner1968 Mar. 4 at 6:04 PM

$APLS well Mikael Dolstens made an impact then!

2 · Reply

buylowandwait Mar. 4 at 4:13 PM

$APLS Though the asset of this company should be valued far more than the current enterprise value. The management team leaves bad taste for its management style, and they are going to milk as much from shareholders as they can.

1 · Reply

Johnquest123 Mar. 3 at 2:56 PM

$APLS let the good times roll and keep on rolling!

0 · Reply

Market Cap	2.29B
Revenue (ttm)	1.00B
Net Income (ttm)	22.39M
EPS (ttm)	N/A
PE Ratio	137.62
Forward PE	N/A
Profit Margin	2.23%
Debt to Equity Ratio	1.23

Volume	5,601,900
Avg Vol	2,925,048
Day's Range	N/A - N/A
Shares Out	127.83M
Stochastic %K	2%
Beta	0.26
Analysts	Strong Sell
Price Target	$33.40